[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
March 21, 2007

Sunshine Laws and the Pharmaceutical Industry

Author Affiliations
 

Author Affiliations: Aetna Inc, Hartford, Conn (Dr Brennan); and Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass (Dr Mello).

JAMA. 2007;297(11):1255-1257. doi:10.1001/jama.297.11.1255

Recent research would suggest that the US public should be pleased with the role the pharmaceutical industry plays in advancing public health. Somewhat surprisingly, given widespread concerns about the cost-inflating effects of drugs and other medical technologies, Cutler and colleagues have shown that spending on medical technology is generally cost-effective.13 This is particularly true of new drugs, which often have contributed to stunning decreases in morbidity and mortality—for example, in cardiovascular disease.4,5 It appears that the huge investments needed to bring new drugs and medical devices to market are wise.

First Page Preview View Large
First page PDF preview
First page PDF preview
×